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and an increase in free zinc. Redox stress is thought to affect many 
intracellular metabolic processes including inhibition of reductases and, 
ultimately, induction of cell death. Oxidative stress induced by MGd 
appears to exceed the NRF-2 mediated antioxidant capacity in A549 
lung cancer cells. The mechanism of action and activity of MGd may 
be particularly well suited for therapy of NSCLC.
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Serum biomarkers predict response to combination celecoxib and 
erlotinib therapy in advanced non-small cell lung cancer
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Background: Cyclooxygenase-2 (COX-2) overexpression may 
mediate resistance to EGFR TK inhibition through prostaglandin E2 
(PGE2)-dependent promotion of epithelial to mesenchymal transition 
(EMT). The suppression of epithelial markers such as E-cadherin can 
to non-small cell lung cancer (NSCLC) resistance to erlotinib. In addi-
tion, PGE2 can downregulate E-cadherin expression by upregulating 
the transcriptional repressors of E-cadherin, ZEB1 and Snail. These 
ﬁndings suggest that COX-2 inhibition may enhance the efﬁcacy of 
EGFR TKI therapy in NSCLC, and markers of EMT may be important 
in predicting response to this combination of targeted therapy. 
Methods: A phase I, dose escalation trial to was performed investigat-
ing the combination of celecoxib and erlotinib in patients with ad-
vanced NSCLC. Soluble E-cadherin was evaluated by ELISA in patient 
serum at baseline and weeks 4 and 8 of treatment. Other markers of 
COX-2 gene expression and EMT were evaluated by ELISA, including 
matrix metalloproteinase (MMP)-9, MMP-2, tissue inhibitor of MMP 
(TIMP1), and CCL15. 
Results: 22 patients had serum samples available for evaluation. Serum 
E-cadherin, MMP-9, MMP-2, TIMP1 and CCL15 were analyzed 
according to best response (PR, SD or PD). We found a signiﬁcant 
decrease in soluble E-cadherin between baseline and week 8 in pts with 
PR when compared to those with SD or PD (p = 0.021). In patients 
who responded to the combination therapy, baseline MMP-9 was sig-
niﬁcantly lower compared to non-responders (p = 0.006). MMP-2 and 
TIMP1 showed no signiﬁcant change based on patient response, and 
CCL15 decreased in patients with PR. 
Conclusions: Soluble E-cadherin, MMP-9 and other downstream 
markers of COX-2 gene expression may be useful for assessing 
response to combination celecoxib and erlotinib in pts with advanced 
NSCLC. A randomized Phase II trial is planned comparing erlotinib 
and celecoxib with erlotinib plus placebo in advanced NSCLC, to 
evaluate the efﬁcacy of this combination therapy and to assess these 
and other biomarkers in both serum and tumor tissue. 
Supported by Phase One Foundation Award, UCLA Lung Cancer 
SPORE NCI P50 CA 90388 and GLAVAHS CDA. 
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Combined 131I-chTNT and external irradiation for solid tumors in 
the mouse
Wu, Gang 
Union Hospital, Wu Han, China
Objective: To compare the difference of only 131I-chTNT and 
combined 131I-chTNT and external irradiation for solid tumors in the 
mouse. 
Methods: chTNT-3, a chemic monoclonal antibody directed cell 
nucleus in the necrotic parts of tumor, can play important roles in many 
tumors. chTNT-3 is iodinated with 131I. Among twenty-four nude mice 
with tumor cells xenografts(human adenocarcinoma of lung) used in 
the study, were divided into six groups and given different treatment 
protocols. Total accumulated dose, 24h percentage of injected activity 
per gram of tumor tissue and accumulated dose per injected activity 
were compared between there different groups. 
Results: In the study, better yields in terms of total accumulated dose, 
24h percentage of injected activity per gram of tumor tissue and accu-
mulated dose per injected activity were seen in the ﬁrst group. 
Conclusions: Enhanced effects can be achieved by combined external 
irradiation with radioimmunotherapy using the monoclonal anticyto-
keratin antibody 131 I-chTNT. 20Gy of external irradiation should be 
given prior to Mab injection.
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soluble vascular endothelial growth factor receptor 1( s VEGFR1) 
transducted by sendai virus using dendritic cells as vector inhibited 
HUVEC activity in vitro and growth and metastasis of Lewis lung 
cancer in vivo
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Objective: To evaluate the anticancer effect of s VEGFR1 transducted 
by sendai virus using dendritic cells(DCs) as vector in vitro and in vivo
Methods: Isolated and puriﬁed mouse bone marrow derived DCs were 
infected by sendai viruses at different moi, which were transducted by 
s VEGFR1(s VEGFR1-SeV-DCs). The culture medium was collected 
to treat HUVEC in vitro to analysis the proliferation, apoptosis, s 
VEGFR1-SeV-DCs were injected to Lewis lung cancer bearing mice to 
evaluate the survival time, growth and metastasis in vivo.
Results: s VEGFR1-SeV-DCs inhibited the proliferation of HUVEC, 
and induced apoptosis in vitro, s VEGFR1-SeV-DCs inhibited the 
growth and metastasis of Lewis lung cancer in vivo, and inhibited 
proliferation of lung cancer, induced apoptosis of cancer cells and 
inhibited the angiogenesis and improved immunological response.
Conclusions: SeV-DC was an effective vector in immuno-gene 
therapy, s VEGFR1 was an interesting gene in gene therapy, it is need 
to be studied further in future.
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Combination of low-dose chemotherapy with intratumoral 
dendritic cell vaccine is beneficial for the treatment of murine non 
small cell lung cancer
Zhong, Hua 
Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, 
China
At present study, we evaluated an antitumor potential of low- dose che-
motherapy combined with intratumoral dendritic cells (DC) vaccine in 
the s.c. murine Lewis lung cancer model. The dose of chemotherapeu-
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tic drug paclitaxel (50 nM) chosen for this study caused less then 30% 
death of 3LL cancer cells in vitro, was not toxic to DC and stimulated 
DC maturation and function in vitro. First, we found that 3LL cells 
inhibited DC maturation and function in vitro and immunosuppressive 
effect of 3LL cells was signiﬁcantly decreased after their pretreat-
ment with paclitaxel. Next, we investigated a combination of low dose 
chemotherapy and DC vaccine in vivo using s.c. Lewis lung carcinoma 
model. Animals were divided into four groups: (1) non-treated, (2) 
treated with intraperitonel injection of paclitaxel 9 days after tumor in-
oculation, (3) treated with intratumoral injection of immature DC, and 
(4) intraperitoneal injection of paclitaxel followed by intratumoral DC 
injection. We observed a signiﬁcant decrease in tumor growth in-group 
4 associated with CD4 and CD8 T cells inﬁltration of tumor and IFN-γ 
production by lymph node cells. Using microdialisis technique for mea-
suring cytokines, chemokines, and growth factors released within the 
tumor bed in dynamics in live freely moving animals, we determined 
whether the combination therapy alters immunological network at the 
tumor site. Our results demonstrated that the combination of low-dose 
paclitaxel and DC vaccine resulted in increase in intratumoral MCP-1, 
IP-10, and KC chemokines and decrease in intratumoral IL-1α. 
Novel Therapeutics: New Horizon and Others
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A novel trans-lymphatic drug delivery system of gelatin sponge 
impregnated with PLGA-Paclitaxel microspheres for the control of 
lymphatic metastasis in lung cancer
Liu, Jiang 
University of Toronto, Toronto, ON, Canada
Objectives: Lymphatic metastasis is a critical prognostic factor for 
lung cancer. Delivering therapeutic agent to the lymphatic system poses 
a signiﬁcant challenge. The objective of the study is to develop a target-
ed drug delivery system to control lymphatic metastasis in lung cancer. 
Methods: Paclitaxel (PTX) loaded Poly(lactide-co-glycolide) micro-
spheres (PLGA-PTX) were constructed using a spray drying technique. 
The microspheres were incorporated into gelatin sponge to form an 
implantable device. The morphology, particle size and drug releasing 
properties of the system were characterized in vitro. Cytotoxicity of 
PLGA-PTX to the H460 human lung cancer cells was examined by clo-
nogenic assay. The pharmacokinetics was studied in Sprague Dawley 
rats with either of the following four regimens (1) PTX 8 mg/kg given 
i.v.; (2) PTX 8 mg/kg given intrapleurally (ipl.); (3) PLGA-PTX (100 
mg/kg) given intrapleurally; (4) gelatin sponge containing PLGA-PTX 
(100 mg/kg) implanted intrapleurally. The dwell time of the chemo-
therapy was 1h, 3h, 8h, 12h, 24h, 48h, 7d, for the former two regimens 
and 12h, 24h, 3d, 7d, 14d, 21d, 28d for the latter two regimens. PTX 
concentrations in lymph node and plasma were determined by LC/MS. 
The area under the concentration vs time curve (AUC) was calculated. 
Therapeutic efﬁcacy was assessed in a nude rats H460 orthotopic lung 
cancer model with 100% incidence of lymphatic metastasis. Fourteen 
days following endobronchial tumor implantation, the lung tumors 
were resected by pneumonectomy. Animals were treated intraopera-
tively with either ipl. implantation of gelatin sponge containing PLGA-
PTX (100 mg/kg), placebo sponge or no treatment (n=10/group). 
Tumor recurrences were examined 32 days later. 
Results: The microspheres had a mean particle size of 3.5 ± 2.1 μm, a 
drug loading of 7.0% (w/w). The system exhibited controlled release 
properties in vitro. PTX and PTX extracted from PLGA-PTX exhib-
ited similar cytotoxic effect on the colony formation of H460 cells. 
The AUC for lymph node was signiﬁcantly higher with ipl. admin-
istration of PLGA-PTX and gelatin sponge containing PLGA-PTX 
(6904.3±245.5 and 6470.3±366.3 μg-d/g respectively) as compare to 
i.v. and ipl. administration of free PTX (10.52±0.27 and 31.47±1.09 
μg-d/g respectively). This represents more than a 6000-fold increase in 
drug exposure for lymphatic tissue after ipl. administration of PLGA-
PTX. Conversely, the AUC of the plasma was lower with PLGA-PTX 
administration as compare to free PTX administration. Lymph node tu-
mor was found in 20% of the treatment group vs 100% of the non-treat-
ment and the placebo controls (p<0.01). In the drug treatment group 
the weight of metastatic lymph nodes was signiﬁcantly lower than that 
of non-treatment and placebo controls. PLGA-PTX microspheres were 
microscopically identiﬁable in the targeted lymph nodes. 
Conclusions: The system combines controlled release properties of 
PLGA-PTX with structural advantages of gelatin matrix. PLGA-PTX 
inhibits lung cancer cell growth in vitro and reduces lymphatic metasta-
sis in vivo. These effects may be attributable to the improved pharma-
cokinetic distribution of PTX to the lymphatic system. 
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Photodynamic therapy with chlorine photosensitizers on the 
central lung cancer
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Background: Photodynamic therapy (PDT) is a novel method for treat-
ment of malignancy. It is effective method for palliation of lung cancer 
and can improve results of combined treatment. Therapeutical improve-
ment in this ﬁeld may result from use of new photosensitizers. The aim 
of this study is to estimate direct results of photodynamic therapy with 
chlorine photosensitizers on the central lung cancer. 
Methods: The photodynamic therapy with chlorine photosensitizers 
(Photolon, Photoditazin) on 41 patients with central lung cancer is 
carried out. 37 males, 4 females, aged 42-81 years (mean 61.5) with 
advanced inoperable bronchogenic cancer and endobronchial luminal 
obstruction were studied. Most patients were at the stage IIIb-IV. The 
histology of the tumors was: non small cell in 36 and small cell in 5 
patients. The pre/post-treatment protocol consisted of: clinical, radio-
logical and bronchoscopic examination, pulmonary function testing. 
Intravenous injection of chlorine photosensitizers (1.5-2.4 mg/kg body 
weight) was given, 2-3 h later the tumor was illuminated with 662 nm 
laser light. We use a ﬂexible ﬁbreoptic bronchoscope for visualiza-
tion and placement of the optical ﬁbre, which was passed through the 
biopsy channel of the instrument to the target tissue. For 3 days after 
the procedure the patients were under special light conditions. PDT 
repeated if necessary.
Results: Positive radiological dynamics in the form of the sanction 
atelektasis elimination of ventilating infringements was observed in 
66,7 % cases. In a month after the PDT bronchoscopy was done (37 
patients) complete response was observed in 23 (62.2 %) cases, partial 
response in 12 (34.4%), in 2 patients reductions of a tumor is not 
revealed. Vital capacity (VC) after PDT increase from 3 % up to 33% 
(mean 20 %). Reduction of cough was noted in 31 (77.5 %) of 40 pa-
tients. Reduction of dyspnoea was noted in 65.8 % patients. Haemoph-
